Background
==========

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia worldwide and increases the risk of ischemic stroke by nearly 5-fold \[[@B1],[@B2]\]. Studies have demonstrated that adjusted-dose vitamin K antagonists (VKAs) significantly decrease the risk of stroke in AF patients versus placebo or aspirin therapy \[[@B3],[@B4]\]. However, VKA use can be challenging given the narrow therapeutic international normalized ratio (INR) range, requirement for periodic INR monitoring, high inter-patient variability in response, numerous drug and food interactions and risks related to non-adherence \[[@B5]\].

In previous meta-analyses \[[@B6]-[@B9]\] the quality of anticoagulation control with VKAs has proven to be poor; with an estimated time spent in the therapeutic INR range (TTR) between 55% and 64%. Numerous study-level factors (e.g., VKA dosing setting) have been shown to be an important determinant of the quality of INR control. Thromboembolic events may occur more frequently at an INR \<2.0 and major hemorrhagic events at an INR \>3.0 \[[@B10]\]. No previous meta-analyses have examined INR control in VKA-experienced as compared to naïve patients as a study-level factor, not all analyses have looked at AF alone, and few have assessed the percentage of INRs in therapeutic range (PINRR) as a quality measure of INR control. Moreover, there has been a substantive increase in the number of studies assessing INRs in patients with AF receiving VKAs in the past few years, lending more power and validity to a systematic assessment of INR control being conducted now.

The primary objective of this systematic review with meta-analyses and meta-regression analyses was to assess VKA INR control in AF patients and the effect of selected study-level factors (including prior VKA treatment experience) on TTR and the PINRR, and to evaluate the relationship between the proportion of VKA-associated hemorrhagic and thromboembolic events that occurred when the INR was above or below the therapeutic range.

Methods
=======

Study selection
---------------

A systematic review of MEDLINE, CENTRAL and EMBASE (from 1990 through June 2013) was performed. Our search strategy for Medline is provided in the Additional file [1](#S1){ref-type="supplementary-material"}. Two investigators reviewed all potentially relevant articles independently, with disagreement resolved by a third investigator. Studies were selected for inclusion on the basis of the following criteria: English full-text randomized controlled trials (RCT), prospective cohort studies or retrospective analyses; contained ≥50 patients in each treatment group; conducted in adult patients (≥18 years of age) receiving dose-adjusted VKA with AF as their primary reason for anticoagulation; and INR control reported as TTR, PINRR or report an INR measurement at (within 48 hours of the event) or near (more than 48 hours from the event) the time of a hemorrhagic or thromboembolic event. Studies were excluded if the duration of study was \<3 months, the target INR range was other than 2.0 to 3.0, or patient population overlapped with another study. Manual backward citation tracking of references from identified studies and review articles was also performed to identify additional relevant studies.

Data abstraction
----------------

Two investigators used a common data abstraction tool, but independently abstracted all data. If a disagreement arose it was resolved by a third investigator. The following study-level information was obtained: author identification, year of publication (1990--2000, 2001--2007 or 2008--2013), whether patients were VKA-naïve (\<30% of the population receiving a VKA prior to entering the study) or experienced (\>70% of the population receiving a VKA prior to entering the study), geographic location of the study (Europe/United Kingdom (UK), Asia, North America, multinational or other), duration of VKA treatment , specific VKA used, interpolation method, whether patients were utilizing VKA self-management to monitor INR control and the study setting (anticoagulation clinic, RCT, or community/standard practice). The setting was designated using the following definitions: an anticoagulation clinic, if the study took place in an anticoagulation clinic or if the stated role of the study clinicians in patient care was limited to managing anticoagulation; a randomized trial if random allocation was employed to assign subjects to receive warfarin or another non-warfarin therapy; and all others were classified as community practice.

Measures of INR control and outcomes were abstracted from each study including TTR, time spent above range, time spent below range, PINRR, proportion of INR measurements above and below therapeutic range and clinical outcomes of major hemorrhage and thromboembolic events. Major hemorrhages included intracranial hemorrhage (ICH) and extracranial bleeding (bleeding requiring hospitalization, blood transfusion or surgical treatment or occurring at a critical anatomical location). All thromboembolic events were abstracted including ischemic stroke, systemic emboli, venous thromboembolism and myocardial infarction. INR measurements at or near each thromboembolic and hemorrhagic event were abstracted when reported.

Statistical analysis
--------------------

TTR and PINRR for each study group, as well as the time/proportions below and above range for these measures were expressed as an incidence density using a person-time approach. The numerator was calculated as the proportion of time that the group spent within, below or above the INR range or proportion of INR measurements in, below, or above range multiplied by person-years of follow-up. The denominator was the total person-years of observation for each study group (or the mean/median observation time multiplied by the number of patients in each study group, if person-years of follow-up for the VKA arm(s) in a study was not reported). Ninety-five percent confidence intervals (CIs) were calculated for each incidence density using the Wilson score method without continuity correction. For the purposes of these analyses, all studies were pooled using a random-effects model.

In order to determine how study--level factors influenced TTR or PINRR, both subgroup and meta-regression analyses were conducted. Meta-regression analysis allows evaluating the effect of any given influencing factor independent of the effect of other aspects. A multiple linear mixed method model using both random- and fixed-effects was utilized for meta-regression, which was weighted by the inverse of the variance of TTR or PINRR. Fixed-effects were assumed for study-level factors, including the following covariates: prior experience with VKAs (naïve, experienced, mixed/not reported), study design (community, anticoagulation clinic, RCT), study year (from 1990--2000 and 2001--7, 2008--2013), use of self-management or not, interpolation method (linear or other), geographic region (North America \[United States and Canada\], Europe/UK, Asia, multinational, other) and duration of VKA treatment (\<1 year, ≥1 year). No hierarchy was used in the model for these covariates.

The weighted proportion of thromboembolic and hemorrhagic events occurring outside of the INR range for each study group was also calculated. For this analysis, the numerator was the number of thromboembolic events occurring below an INR of 2.0 or the number of hemorrhagic events above an INR of 3.0. The denominators were the total number of thrombotic or hemorrhagic events for each study group. Ninety-five percent CIs were calculated for each proportion using the Wilson score method without continuity correction. Again, all studies were pooled using a random-effects model. Since not all studies measured INR values at the exact time of adverse outcomes, we conducted two separate analyses, one pooling studies regardless of the elapsed time between the INR measurement and the adverse event; and a second (sensitivity analysis) including only those studies specifically stating an INR was measured within 48 hours of the event.

For all meta-analyses, statistical heterogeneity was determined using the I^2^ statistic (with an I^2^ \> 50% signifying an important degree of statistical heterogeneity) and publication bias was assessed using the Egger's weighted regression statistic (with a p \< 0.05 suggesting a higher likelihood of publication bias) and through review of funnel plots (scatterplots of effect size against standard error, where the each dot represents a study effect estimate and the vertical line represents the pooled effect). Statistical analyses were performed using StatsDirect version 2.7.6 (StatsDirect Ltd., Cheshire, England), SAS, version 9.2 (SAS Institute Inc., Cary, NC), and SPSS 15.0 for Windows (SPSS, Inc, Chicago, IL).

Results
=======

We identified 5,326 citations, of which 5,231 were excluded (Figure [1](#F1){ref-type="fig"}). Ninety-five articles met our inclusion and exclusion criteria \[[@B11]-[@B103]\]. Sixty-eight studies reported measures of INR control representing 87 VKA study arms, and 43 studies reported an INR at or near the time of the adverse event (16 studies reported both and were included in both analyses).

![**Flow diagram showing results of the literature search.** CCTR = Cochrane Central Register of Controlled Trials; RCT = randomized controlled trial; OBS = observational; AF = atrial fibrillation; VKA = vitamin K antagonist; INR = international normalized ratio; TTR = time in therapeutic range; PINRR = proportion of INR measurements in range.](1477-9560-12-14-1){#F1}

Of the 87 VKA study groups that reported a measure of INR control, 17 reported data on patients with no prior VKA exposure whereas 47 enrolled patients who were VKA-experienced and 23 did not report prior VKA exposure data or had mixed enrollment. Twenty-eight VKA groups were from RCTs, 27 were conducted in an anticoagulation clinic setting, and 32 were in a community practice setting (Table [1](#T1){ref-type="table"}). Thirty-nine VKA study groups were recruited in Europe/UK, 5 from Asia, 13 were multinational, 1 from Israel and 29 from North America. The mean age ranged from 62 to 92 years (median, 72 years), the number of VKA-treated patients ranged from 55 to 11,770 (median, 249), and the person-years of VKA therapy ranged from 17 to 30,188 (median, 399). Of the 43 identified studies that reported an INR with an adverse event, 16 were RCTs, 14 were conducted in an anticoagulation clinic, and 13 were from community practice with the number of VKA-treated patients ranged from 55 to 9,217 (median, 288) (Table [1](#T1){ref-type="table"}).

###### 

Demographics of included studies

  **Study, Year**                           **Study design/setting**   **VKA-treated N**   **Mean age**   **VKA experience, %**   **Geographic region**   **Interpolation method**   **Self -management**   **Duration of therapy, months (Patient-years)**   **VKA studied**
  ---------------------------------------- -------------------------- ------------------- -------------- ----------------------- ----------------------- -------------------------- ---------------------- ------------------------------------------------- -----------------
  Abdelhafiz 2004 \[[@B11]\]                      PD/AC clinic                402               72                 0%                    Europe                    Linear                     N                                19 (637)                              W
  Abdelhafiz (\<75) 2008 \[[@B12]\]               PD/AC clinic                203               64                 0%                    Europe                    Linear                     N                                19 (321)                              W
  Abdelhafiz (≥75) 2008 \[[@B12]\]                    199                     80             19 (315)                                                                                                                                                        
  Akdeniz 2005 \[[@B13]\]                         PD/Community                208               66                 NR                    Turkey                      \-                       \-                                  \-                                 W
  Albers 2005 \[[@B14]\]                              RCT                    1962               72                 85%                 N. America                  Linear                     N                                20 (3270)                             W
  Anderson 2004 \[[@B15]\]                        RD/AC clinic                87                NR                100%                 N. America                    NR                       N                                 12 (87)                              W
  Ansell (Italy) 2007 \[[@B16]\]                  RD/AC clinic                177               72                100%                Multinational                Linear                     N                                12 (177)                              W
  Ansell (Spain) 2007 \[[@B16]\]                  RD/AC clinic                218               72              12 (218)                    A                                                                                                                
  Ansell (US) 2007 \[[@B16]\]                     RD/Community                686               75              12 (686)                    W                                                                                                                
  Ansell (Canada) 2007 \[[@B16]\]                 RD/Community                152               74              12 (152)                    W                                                                                                                
  Ansell (France) 2007 \[[@B16]\]                 RD/Community                278               73              12 (278)                    F                                                                                                                
  Aronow 1999 \[[@B17]\]                          PD/Community                125               83                 NR                  N. America                    NR                       N                                34 (354)                              W
  Boulanger 2006 \[[@B18]\]                       RD/Community               6454               68                 65%                 N. America                  Linear                     N                                12 (6454)                             W
  Burton (\<75) 2006 \[[@B19]\]                   RD/Community                260               NR                Mixed                  Europe                    Linear                     N                                25 (539)                              W
  Burton (\>75) 2006 \[[@B19]\]                       341                  15 (414)                                                                                                                                                                          
  Cafolla (Manual) 2011 \[[@B20]\]                RD/Community                576               NR                100%                   Europe                    Linear                     N                                 8 (384)                             A,W
  Cafolla 2012 \[[@B21]\]                         PD/AC clinic                57                85                100%                   Europe                    Linear                     N                                 18 (86)                              W
  Cheung 2005 \[[@B22]\]                          RD/Community                555               70                100%                    Asia                       \-                       N                                19 (893)                              W
  Chung 2011 \[[@B23]\]                               RCT                     75                65                 55%                    Asia                     Linear                     N                                 3 (19)                               W
  Connolly 1991 \[[@B24]\]                            RCT                     187               68                 0%                  N. America                  Linear                     N                                15 (234)                              W
  Connolly 2006 \[[@B25]\]                            RCT                    3371               70                 78%                 N. America                  Other                      N                                15 (4214)                            NR
  Copland 2001 \[[@B26]\]                         RD/AC Clinic                328               70                100%                     UK                        \-                       N                                21 (458)                              W
  Currie (stable) 2005 \[[@B27]\]                 RD/Community                787               74                100%                   Europe                    Linear                     N                                35 (2282)                             W
  Currie (unstable) 2005 \[[@B27]\]                   726                     78            35 (2105)                                                                                                                                                        
  Dentali 2012 \[[@B28]\]                         PD/AC Clinic                221               75                 100                   Europe                      \-                       N                                 3 (663)                              W
  DiMarco 2005 \[[@B29]\]                             RCT                     NR                70                 NR                  N. America                    \-                       N                                 42 (−)                               W
  Dimberg (control SP) 2012 \[[@B30]\]            RD/Community                84                69                100%                   Europe                    Linear                     N                                 12(84)                               W
  Dimberg (control ACC) 2012 \[[@B30]\]           RD/AC clinic                271               72               12(271)                                                                                                                                     
  EAFT 1995 \[[@B31]\]                                RCT                     214               71                 0%                    Europe                      \-                       N                                24 (377)                            W,A,F
  Ellis 2009 \[[@B32]\]                               RCT                     66                68                 97%                 N. America                  Linear                     N                                 3 (17)                               T
  Evans 2000 \[[@B33]\]                           PD/AC clinic                288               76                 0%                    Europe                      NR                       N                                24 (576)                              W
  Evans 2001 \[[@B34]\]                           PD/AC clinic                214               78                 NR                    Europe                      NR                       N                                24 (448)                              W
  Ezekowitz 2007 \[[@B35]\]                           RCT                     70                69                100%                Multinational                  NR                       N                                 3 (18)                               W
  Fang 2004 \[[@B36]\]                            RD/AC Clinic                170               78                 100                 N. America                    \-                       N                                   \-                                 W
  Gallagher 2011 \[[@B37]\]                       RD/Community               18113              73                 72%                   Europe                    Linear                     N                               20 (30188)                             W
  Garcia (naïve) 2013 \[[@B38]\]                      RCT                    3888               70                 0%                 Multinational                Linear                     N                                22 (7128)                             W
  Garcia (exp) 2013 \[[@B38]\]                        5193                    70               100%             22 (9521)                                                                                                                                    
  Gladstone 2009 \[[@B39]\]                       RD/Community                423               78                 100                 N. America                    \-                       N                                   \-                                 W
  Go 2003 \[[@B40]\]                              RD/AC clinic               7445               71                Mixed                N. America                  Linear                     N                               21 (12958)                             W
  Gullov 1998 \[[@B41]\]                              RCT                     170               73                 0%                    Europe                    Linear                     N                                25 (355)                              W
  Gullov 1999 \[[@B42]\]                              RCT                     170               73                  0                    Europe                    Linear                     N                                25 (355)                              W
  Gurwitz 1997 \[[@B43]\]                         RD/Community                117               83                 32%                 N. America                  Linear                     N                                12 (117)                              W
  Hannon 2011 \[[@B44]\]                          PD/Community                43                77                 100                   Europe                      \-                       N                                   \-                                 W
  Hart 2011 \[[@B45]\]                                RCT                     523               NR                  0                  N. America                    \-                       N                                13 (575)                              W
  Heidinger 2000 \[[@B46]\]                       RD/Community                753               62                100%                   Europe                      NR                       Y                                12 (769)                             NR
  Hellemons 1999 \[[@B47]\]                           RCT                     131               70                  0                    Europe                      \-                       N                                32 (354)                             P,A
  Ho (hypertension) 2011 \[[@B48]\]               RD/Community                278               70                 NR                 Multinational                Linear                     N                                48 (1112)                             W
  Ho (no HTN) 2011 \[[@B48]\]                         198                     69             48 (792)                                                                                                                                                        
  Holmes 2009 \[[@B49]\]                              RCT                     244               73                100%                Multinational                  NR                       N                                18 (366)                              W
  Hori 2012 \[[@B50]\]                                RCT                     250               71                 90%                    Asia                     Linear                     N                                30 (625)                              W
  Hylek 2003 \[[@B51]\]                           RD/Community                188               76                 100                 N. America                    \-                       N                                   \-                                 W
  Hylek 2007 \[[@B52]\]                           PD/AC clinic                472               77                 0%                  N. America                  Linear                     N                                12 (360)                              W
  Jacobs 2009 \[[@B53]\]                          RD/Community                90                NR                 85%                 N. America                  Linear                     N                                 12 (90)                              W
  Jones 2005 \[[@B54]\]                           RD/Community               2223               72                100%                   Europe                    Linear                     N                                31 (5743)                             W
  Kalra 2000 \[[@B55]\]                           PD/AC clinic                167               77                 0%                    Europe                    Linear                     N                                24 (296)                              W
  Kim 2009 \[[@B56]\]                             RD/AC clinic                129               64                100%                    Asia                     Other                      N                                24 (258)                              W
  Kim 2010 \[[@B57]\]                             PD/AC clinic                499               73                100%                 N. America                  Linear                     N                                 5 (208)                              W
  Kulo (warfarin) 2009 \[[@B58]\]                 PD/Community                60                66                100%                   Europe                      NR                       N                                 12 (60)                              W
  Kulo (acenocoumarol) 2009 \[[@B58]\]                 57                     68             12 (57)                A                                                                                                                                        
  Lee 2012 \[[@B59]\]                             RD/Community                200               67                 NR                     Asia                     Linear                     N                                42 (700)                              W
  Malik 2000 \[[@B60]\]                           RD/AC clinic                247               68                100%                 N. America                  Other                      N                                13 (268)                              W
  Mant 2007 \[[@B61]\]                                RCT                     488               82                 40%                   Europe                    Linear                     N                                32 (1301)                             W
  Matchar (control) 2002 \[[@B62]\]                   RCT                     317               76                 NR                  N. America                  Linear                     N                                 9 (238)                              W
  Matchar (prior to ACC) 2002 \[[@B62]\]          PD/AC clinic                363               75               9 (272)                                                                                                                                     
  McBride 2007 \[[@B63]\]                         PD/Community                361               71                 90%                   Europe                    Linear                     N                                 9 (271)                              W
  McCormick 2001 \[[@B64]\]                       RD/Community                174               87                100%                 N. America                  Linear                     N                                12 (174)                              W
  Melamed 2011 \[[@B65]\]                         RD/Community                906               72                100%                   Israel                    Linear                     N                                10 (769)                              W
  Menzin 2005 \[[@B66]\]                          RD/AC clinic                600               72                 63%                 N. America                  Linear                     N                                11 (525)                              W
  Morocutti 1997 \[[@B67]\]                           RCT                     454               72                 NR                    Europe                      \-                       N                                   12                                 W
  Neree 2006 \[[@B68]\]                           RD/Community                395               74                100%                   Europe                    Linear                     N                                 4 (132)                            P,A,W
  Nichol (ACC) 2008 \[[@B69]\]                    RD/AC clinic                351               NR                100%                 N. America                  Linear                     N                                31 (920)                              W
  Nichol (UC) 2008 \[[@B69]\]                     RD/Community                756           18 (1165)                                                                                                                                                        
  Njaastad 2006 \[[@B70]\]                        RD/AC clinic                421               NR                 0%                    Europe                    Linear                     N                                14 (475)                              W
  Nozawa 2001 \[[@B71]\]                          PD/Community                156               68                 100                    Asia                       \-                       N                                22 (286)                              W
  Ogawa 2011 \[[@B72]\]                               RCT                     75                72                  0                     Asia                     Linear                     N                                 3 (210)                              W
  Okumura (\<70) 2011 \[[@B73]\]                  PD/Community                208               NR                100%                    Asia                     Linear                     N                                23 (399)                              W
  Olsson 2003 \[[@B74]\]                              RCT                    1703               70                 73%                Multinational                  NR                       N                                16 (2271)                             W
  Ono 2005 \[[@B75]\]                             PD/Community                63                76                  0                     Asia                     Linear                     N                                28 (145)                              W
  Patel 2011 \[[@B76]\]                               RCT                    7133               73                 63%                Multinational                Linear                     N                               20 (11888)                             W
  Pengo 1998 \[[@B77]\]                               RCT                     153               74                 0%                    Europe                    Linear                     N                                14 (179)                              W
  Pengo 2001 \[[@B78]\]                           PD/AC Clinic                433               68                  0                    Europe                    Linear                     N                                17 (615)                             W,A
  Pengo 2010 \[[@B79]\]                               RCT                     132               79                 0%                 Multinational                Linear                     N                                64 (704)                              W
  Perez-Gomez 2004 \[[@B80]\]                         RCT                     237               70                 0%                    Europe                      NR                       N                                33 (556)                              A
  Poli 2007 \[[@B81]\]                            PD/AC clinic                290               82                100%                   Europe                    Linear                     N                                34 (814)                             NR
  Poli 2009 \[[@B82]\]                            PD/AC Clinic                783               75                 0%                    Europe                    Linear                     N                                39 (2567)                             W
  Poli 2009 \[[@B83]\]                            PD/AC clinic                578               75                100%                   Europe                    Linear                     N                                38 (1854)                            NR
  Poli 2009 \[[@B84]\]                            PD/AC clinic                780               75                 100                   Europe                    Linear                     N                                36 (2406)                             W
  Poller (Manual) 2008 \[[@B85]\]                     RCT                    2967               67                 0%                 Multinational                Linear                     N                                17 (4203)                          W, A, P
  Sadanaga 2010 \[[@B86]\]                        PD/Community                259               74                 100                    Asia                       \-                       N                                25 (544)                              W
  Samsa (ACC) 2000 \[[@B87]\]                     RD/AC Clinic                43                69                 NR                  N. America                  Linear                     N                                 9 (32)                               W
  Samsa (Rochester) 2000 \[[@B87]\]               RD/Community                61              9 (46)                                                                                                                                                         
  Samsa (R. Triangle) 2000 \[[@B87]\]             RD/Community                125             9 (94)                                                                                                                                                         
  Schwammenthal 2010 \[[@B88]\]                   PD/Community                111               76                 100                   Israel                      \-                       N                                   \-                                 W
  Sconce (vitamin K) 2007 \[[@B89]\]                  RCT                     35                75                100%                   Europe                    Linear                     N                                 6 (18)                               W
  Sconce (placebo) 2007 \[[@B89]\]                     35                     74                                                                                                                                                                             
  Shen 2007 \[[@B90]\]                            RD/Community                NR                72                 55%                 N. America                    NR                       N                               40 (24179)                             W
  Singer 2009 \[[@B91]\]                          RD/Community               9217               77                 100                 N. America                    \-                       N                               72 (33497)                             W
  SPAF III 1996 \[[@B92]\]                            RCT                     523               71                 56%                 N. America                    NR                       N                                13 (567)                              W
  Sullivan (women) 2012 \[[@B93]\]                    RCT                    1594               71                 87%                Multinational                Linear                     N                                42 (5579)                             W
  Sullivan (men) 2012 \[[@B93]\]                      2466                    68               86%              42 (8631)                                                                                                                                    
  Tincani 2009 \[[@B94]\]                         PD/AC Clinic                90                92                100%                   Europe                    Linear                     N                                 12 (90)                              W
  Van Spall 2012 \[[@B95]\]                           RCT                    6022               72                 47%                Multinational                Linear                     N                               24 (12044)                             W
  Voller (self-mgmt) 2005 \[[@B96]\]                  RCT                     101               65                 0%                    Europe                      NR                       Y                                 8 (68)                              NR
  Voller (UC) 2005 \[[@B96]\]                         101                     64                N                                                                                                                                                            
  Walker (MHC) 2011 \[[@B97]\]                    RD/AC Clinic                22                NR                100%                 N. America                  Linear                     N                                 12 (22)                              W
  Walker (no MHC) 2011 \[[@B97]\]                      62                   12 (62)                                                                                                                                                                          
  Wieloch (AF) 2011 \[[@B98]\]                    RD/Community               11770              73                100%                   Europe                    Linear                     N                               12 (11770)                             W
  Weitz 2010 \[[@B99]\]                               RCT                     250               66                 35%                 N. America                  Linear                     N                                 3 (63)                               W
  Wyse 2002 \[[@B100]\]                               RCT                     NR                70                 NR                  N. America                    \-                       N                                   42                                 W
  Yamaguchi 2000 \[[@B101]\]                          RCT                     55                66                 NR                     Asia                       \-                       N                                22 (101)                              W
  Yasaka 2001 \[[@B102]\]                         PD/Community                88                                   100                    Asia                       \-                       N                                22 (161)                              W
  Yousef 2004 \[[@B103]\]                         RD/Community                739               73                100%                   Europe                      NR                       N                                24 (1484)                             W

VKA = vitamin K antagonist; RCT = randomized controlled trial; RD = retrospective design; PD = prospective design; AC clinic = anticoagulation clinic; AF = atrial fibrillation; NR = not reported; N = North; VKA = Vitamin K Antagonist; W = warfarin; A = acenocoumarol; T = tecarfarin; P = phenprocoumon; F = fenprocoumon.

For the first meta-analysis, 78 out of 87 (90%) study groups reported a TTR and 55 (63%) reported the time spent below and above range; 22 of 87 (25%) study groups reported a PINRR and 21 (24%) reported the percent of INR measures below and above range (Table [2](#T2){ref-type="table"}). Thirteen study groups (15%) reported both TTR and PINRR. Overall, patients spent 61% of their TTR (95% CI, 59--62%), 25% (95% CI, 23--27%) below, and 14% (95% CI, 13-15%) above range. Similarly for PINRR, 56% of INR measurements were in the therapeutic range (95% CI, 53--59%), 26% (95% CI, 23--29%) below and 13% (95% CI, 11-17%) above range. Statistical heterogeneity was observed to be high between the groups included in these analyses (I^2^ ≥ 97%). The likelihood of publication bias appeared low for TTR, time above range, PINRR, and proportion of INR measurements below and above range. However, publication bias was deemed more likely for the time below range analysis (Egger's p = 0.03) (Additional file [1](#S1){ref-type="supplementary-material"}).

###### 

Time in range and percentage of INR values in range and major adverse event rates

  **Study, year**                        **N**   **TTR, %**   **PINRR, %**   **Event rate, % per patient-year**                                    
  ------------------------------------- ------- ------------ -------------- ------------------------------------ ------ ------ ------ ------ ----- ------
  Abdelhafiz 2004 \[[@B11]\]              402        66           19.7                      14.3                   \-     \-     \-    1.7    \-     \-
  Abdelhafiz (\<75) 2008 \[[@B12]\]       203        58            16                        26                    \-     \-     \-    1.6     0     \-
  Abdelhafiz (≥75) 2008 \[[@B12]\]        199        58            16                        26                    \-     \-     \-    1.9     0     \-
  Albers 2005 \[[@B14]\]                 1962        68            20                        12                    \-     \-     \-    2.8    0.2   1.1
  Anderson 2004 \[[@B15]\]                87         \-            \-                        \-                   60.4   25.2   14.3    \-            
  Ansell (Italy) 2007 \[[@B16]\]          177       68.9           21                       10.1                   60    26.3   13.6    \-    \-     \-
  Ansell (Spain) 2007 \[[@B16]\]          218       64.4          18.6                       17                    59    23.3   17.7    \-    \-     \-
  Ansell (US) 2007 \[[@B16]\]             686        57           29.1                      13.9                  50.8    32    17.3    \-    \-     \-
  Ansell (Canada) 2007 \[[@B16]\]         152        61           25.9                      13.1                  58.4   27.6    14     \-    \-     \-
  Ansell (France) 2007 \[[@B16]\]         278       58.1          15.4                      26.5                  51.3   19.7    29     \-    \-     \-
  Aronow 1999 \[[@B17]\]                  125        \-            \-                        \-                    68     26     6      \-    \-    11.3
  Boulanger 2006 \[[@B18]\]              6454        48            38                        14                    \-     \-     \-    2.8    \-     \-
  Burton (\<75) 2006 \[[@B19]\]           260        68            17                        15                    \-     \-     \-    2.8            
  Burton (\>75) 2006 \[[@B19]\]           341        68            19                        13                    \-     \-     \-    2.4         
  Cafolla (Manual) 2011 \[[@B20]\]        576       60.4           \-                        \-                    \-     \-     \-     \-    \-     \-
  Cafolla 2012 \[[@B21]\]                 57        64.4           \-                        \-                    \-     \-     \-     0     \-     \-
  Chung 2011 \[[@B23]\]                   75        45.1          43.9                      10.9                   \-     \-     \-    10.5    0     0
  Connolly 1991 \[[@B24]\]                187       43.7          39.6                      16.6                   \-     \-     \-    2.1    0.4   2.1
  Connolly 2006 \[[@B25]\]               3371       63.8          20.8                      15.4                   \-     \-     \-    2.2    \-    1.0
  Currie (stable) 2005 \[[@B27]\]         787       74.9           \-                        \-                    \-     \-     \-    0.4    \-     \-
  Currie (unstable) 2005 \[[@B27]\]       726       55.7           \-                        \-                    \-     \-     \-    1.2    \-     \-
  Dimberg (UC) 2012 \[[@B30]\]            84        64.3           \-                        \-                    \-     \-     \-     \-    \-     \-
  Dimberg (ACC) 2012 \[[@B30]\]           271       73.6           \-                        \-                    \-     \-     \-     \-    \-     \-
  Ellis 2009 \[[@B32]\]                   66        71.4           \-                        \-                   70.7   16.0   13.3   5.8            
  Evans 2000 \[[@B33]\]                   288        55            26                        19                    \-     \-     \-    3.1    0.5   5.5
  Evans 2001 \[[@B34]\]                   214        66            \-                        \-                    \-     \-     \-    3.1    0.7   4.2
  Ezekowitz 2007 \[[@B35]\]               70        57.2           \-                        \-                    \-     \-     \-     0     \-     \-
  Gallagher 2011 \[[@B37]\]              18113      63.1          20.7                      16.2                   \-     \-     \-     \-    \-     \-
  Garcia (naïve) 2013 \[[@B38]\]         3888       61.4           \-                        \-                    \-     \-     \-    3.0    0.8    \-
  Garcia (exp) 2013 \[[@B38]\]           5193       69.1           \-                        \-                    \-     \-     \-    3.2    0.8    \-
  Go 2003 \[[@B40]\]                     7445       62.5          26.8                      10.7                   \-     \-     \-    1.5    0.4   1.1
  Gullov 1998 \[[@B41]\]                  170        73            18                        9                     \-     \-     \-    1.1    0.6   0.8
  Gurwitz 1997 \[[@B43]\]                 117       39.6          44.8                      15.6                   \-     \-     \-     \-    \-     \-
  Heidinger 2000 \[[@B46]\]               753        \-            \-                        \-                   69.5   23.5   7.0    1.7    \-     \-
  Ho (HTN) 2011 \[[@B48]\]                278       49.7          45.4                      4.9                    \-     \-     \-    1.7    0.5   2.2
  Ho (no HTN) 2011 \[[@B48]\]             198       49.8          44.2                      6.0                    \-     \-     \-                
  Holmes 2009 \[[@B49]\]                  244        66            \-                        \-                    \-     \-     \-    2.7    \-    1.6
  Hori 2012 \[[@B50]\]                    250        \-            \-                        \-                   51.8   43.8   4.2    0.8          0.3
  Hylek 2007 \[[@B52]\]                   472        58            29                        11                    \-     \-     \-    7.2    2.5    \-
  Jacobs 2009 \[[@B53]\]                  90         49            35                        15                    \-     \-     \-    5.6            
  Jones 2005 \[[@B54]\]                  2223       68.9          16.7                      15.4                  53.4    \-     \-     \-    \-     \-
  Kalra 2000 \[[@B55]\]                   167        61            26                        13                    \-     \-     \-    1.4    0.3   2.0
  Kim 2009 \[[@B56]\]                     129        \-            \-                        \-                   60.9   31.2   9.1     0             
  Kim 2010 \[[@B57]\]                     499       73.4           \-                        \-                    \-     \-     \-     \-    \-     \-
  Kulo (warfarin) 2009 \[[@B58]\]         60         \-            \-                        \-                   51.8   42.8   5.4     \-    \-     \-
  Kulo (acenocoum) 2009 \[[@B58]\]        57         \-            \-                        \-                   53.6   35.9   10.5    \-    \-     \-
  Lee 2012 \[[@B59]\]                     200       48.5           \-                        \-                    \-     \-     \-    6.6    \-     \-
  Malik (AF) 2000 \[[@B60]\]              247       58.9          27.4                      14.1                   \-     \-     \-     \-    \-     \-
  Mant 2007 \[[@B61]\]                    488        67            19                        14                    \-     \-     \-    1.9    \-    0.8
  Matchar (control) 2002 \[[@B62]\]       317       52.3          31.8                      15.9                   \-     \-     \-    2.1    \-     \-
  Matchar (ACC) 2002 \[[@B62]\]           363       55.6          31.2                      13.1                   \-     \-     \-    2.2    \-     \-
  McBride 2007 \[[@B63]\]                 361        56            16                        28                    \-     \-     \-     \-    \-     \-
  McCormick 2001 \[[@B64]\]               174        51            36                        13                    \-     \-     \-     \-    \-     \-
  Melamed 2011 \[[@B65]\]                 906       48.6          32.0                      19.3                   \-     \-     \-     \-    \-     \-
  Menzin 2005 \[[@B66]\]                  600        62            25                        13                    \-     \-     \-    3.6    \-    1.0
  Neree 2006 \[[@B68]\]                   395        53            \-                        \-                   52.8   8.7    38.5   4.4    \-     \-
  Nichol (ACC) 2008 \[[@B69]\]            351        68            21                        11                    \-     \-     \-    2.3    \-     \-
  Nichol (UC) 2008 \[[@B69]\]             756        42            49                        9                     \-     \-     \-    6.3    \-     \-
  Njaastad 2006 \[[@B70]\]                421       71.5           \-                        \-                    \-     \-     \-    0.8    \-     \-
  Okumura (\<70) 2011 \[[@B73]\]          208        46            51                        2                     \-     \-     \-     \-    \-     \-
  Olsson 2003 \[[@B74]\]                 1703        66            \-                        \-                    \-     \-     \-    2.2    \-    1.9
  Patel 2011 \[[@B76]\]                  7133        55            \-                        \-                    \-     \-     \-    3.4    0.7    \-
  Pengo 1998 \[[@B77]\]                   153        70            18                        12                    \-     \-     \-    2.8    0.6    0
  Pengo 2010 \[[@B79]\]                   132        65            25                        9                     \-     \-     \-    3.0    \-     \-
  Perez-Gomez 2004 \[[@B80]\]             237        65            19                        16                    \-     \-     \-    1.8            
  Poli 2007 \[[@B81]\]                    290        69            15                        16                    \-     \-     \-    2.1    1.4    \-
  Poli 2009 \[[@B82]\]                    783        71            14                        15                    \-     \-     \-    1.4    0.7   0.9
  Poli 2009 \[[@B83]\]                    578        68            16                        16                    \-     \-     \-     \-    \-     \-
  Poller (Manual) 2008 \[[@B85]\]        2967       66.2           \-                        \-                    \-     \-     \-     \-    \-     \-
  Samsa (ACC) 2000 \[[@B87]\]             43        60.3          25.9                      13.8                  54.9   26.7   18.3    \-    \-     \-
  Samsa (Rochester) 2000 \[[@B87]\]       61        46.9          33.9                      19.3                  43.6   33.5   22.9    \-    \-     \-
  Samsa (R. Triangle) 2000 \[[@B87]\]     125       35.6          52.1                      12.2                  34.2   51.0   14.8    \-    \-     \-
  Sconce (vitamin K) 2007 \[[@B89]\]      35         87            \-                        \-                    \-     \-     \-     \-    \-     \-
  Sconce (placebo) 2007 \[[@B89]\]        35         78            \-                        \-                    \-     \-     \-     \-    \-     \-
  Shen 2007 \[[@B90]\]                    NR        54.5          36.3                      9.2                    \-     \-     \-     \-    0.5    \-
  SPAF III 1996 \[[@B92]\]                523        \-            \-                        \-                    61     25     14                   
  Sullivan (women) 2012 \[[@B93]\]       1594        60            29                        11                    \-     \-     \-     \-    \-    0.8
  Sullivan (men) 2012 \[[@B93]\]         2466        63            26                        14                    \-     \-     \-     \-    \-    0.5
  Tincani 2009 \[[@B94]\]                 90         66            19                        14                    \-     \-     \-    5.5    3.3   2.2
  Van Spall 2012 \[[@B95]\]              6022        64            22                        13                    \-     \-     \-     \-    \-     \-
  Voller (self-mgmt) 2005 \[[@B96]\]      101       72.4          13.6                       14                   67.8   15.2   17.0   2.9    \-     \-
  Voller (UC) 2005 \[[@B96]\]             101       63.6          19.5                      16.9                  58.5   22.1   19.4    0     \-     \-
  Walker (MHC) 2011 \[[@B97]\]            22        56.8          34.2                      9.0                    \-     \-     \-     \-    \-     \-
  Walker (no MHC) 2011 \[[@B97]\]         62        65.9          30.7                      3.4                    \-     \-     \-     \-    \-     \-
  Wieloch (AF) 2011 \[[@B98]\]           11770      76.5           \-                        \-                    \-     \-     \-    2.6    \-     \-
  Weitz 2010 \[[@B99]\]                   250       49.7           \-                        \-                    \-     \-     \-    1.6    \-     \-
  Yousef 2004 \[[@B103]\]                 739        \-            \-                        \-                   62.8   22.9   14.3   1.9    \-     \-

AC = Anticoagulation; AF = atrial fibrillation; ICH = Intracranial Hemorrhage; HTN = Hypertension, INR = international normalized ratio; MGMT = Management; N = Number; SP = Standard Practice; TTR = time in the therapeutic range; PINRR = proportion of INR Measurements in range.

Upon meta-regression to determine how study-level factors influenced TTR, community VKA management was associated with less time in range than therapy managed in an anticoagulation clinic or RCT setting, European/UK study patients spent more time in range than North American study patients, and the VKA-naïve (and mixed/not reported) spent less time in range than VKA-experienced patients (Table [3](#T3){ref-type="table"}). For PINRR, no study-level factor was found to be significantly different than the referent upon meta-regression (p \> 0.05) (Table [4](#T4){ref-type="table"}).

###### 

Results of traditional meta-analysis and meta-regression analyses of time in the therapeutic range

                                           **Time spent in therapeutic range**                         
  --------------------------- ----------- ------------------------------------- ---------------------- ---------
  All study groups             78 (100)               61 (59 to 62)                       NA              NA
  Study setting                                                                                             
    AC Clinic                  25 (32.1)              64 (62 to 66)               7.2 (3.2 to 11.2)     \<0.001
    RCT                        26 (33.3)              63 (61 to 65)               9.1 (4.3 to 13.9)     \<0.001
    Community                  27 (34.6)              55 (52 to 59)                    Referent             
  Study year                                                                                                
    1990-2000                  10 (12.8)              53 (46 to 61)              −4.3 (−10.2 to 1.6)     0.16
    2001-2007                  34 (43.6)              64 (62 to 65)               2.2 (−1.7 to 6.1)      0.28
    2008-2013                  34 (43.6)              60 (57 to 63)                    Referent        
  Interpolation method                                                                                      
    NR/Other                   11 (14.1)              63 (60 to 65)               −2.1 (−6.8 to 2.6)     0.38
    Linear                     67 (85.9)              60 (59 to 62)                    Referent             
  Self-management                                                                                           
    No                         77 (98.7)              60 (58 to 62)              −6.8 (−23.7 to 10.1)    0.43
    Yes                         1 (1.3)               72 (68 to 77)                    Referent             
  Geographic region                                                                                         
    Europe/UK                  35 (44.9)              67 (64 to 69)               9.7 (6.0 to 13.4)     \<0.001
    Asia                        3 (3.8)               47 (44 to 49)              −5.5 (−14.7 to 3.7)     0.24
    Other                       1 (1.3)               49 (46 to 52)              −3.0 (−16.1 to 10.1)    0.65
    Multinational              13 (16.7)              61 (57 to 65)               1.8 (−4.1 to 7.7)      0.55
    North America              26 (33.3)              55 (50 to 60)                    Referent             
  VKA experience                                                                                            
    NR/Mixed                   21 (26.9)              54 (49 to 60)              −4.6 (−8.3 to −0.9)     0.02
    No                         17 (21.8)              63 (60 to 66)              −5.3 (−9.6 to −1.0)     0.02
    Yes                        40 (51.3)              63 (60 to 66)                    Referent             
  Duration of VKA treatment                                                                                 
    ≥1 year                    59 (75.6)              62 (60 to 63)               2.7 (−1.7 to 7.1)      0.23
    \<1 year                   19 (24.4)              58 (52 to 65)                    Referent             

AC = anticoagulation; CI = confidence interval; NA = not applicable; No. = number of study arms; NR = Not Reported; RCT = randomized controlled trial; UK = United Kingdom, VKA = Vitamin K Antagonists.

###### 

Results of traditional meta-analysis and meta-regression analyses of proportion of INR measurements in range

                                           **Proportion of INR measurements in range**                         
  --------------------------- ----------- --------------------------------------------- ---------------------- ------
  All study groups             24 (100)                   56 (53 to 59)                           NA             NA
  Study setting                                                                                                   
    AC Clinic                  5 (20.8)                   60 (58 to 62)                  6.9 (−0.02 to 15.2)    0.13
    RCT                        5 (20.8)                   61 (54 to 68)                  5.6 (−0.06 to 17.0)    0.36
    Community                  14 (58.3)                  54 (50 to 57)                        Referent           
  Study year                                                                                                      
    1990-2000                  6 (25.0)                   54 (46 to 64)                  3.3 (−25.3 to 31.9)    0.82
    2001-2007                  13 (54.2)                  56 (54 to 59)                  −2.8 (−14.8 to 9.2)    0.65
    2008-2013                  5 (20.8)                   56 (51 to 62)                        Referent           
  Self-management                                                                                                 
    No                         22 (91.7)                  55 (43 to 57)                  −9.3 (−32.4 to 13.8)   0.45
    Yes                         2 (8.3)                   69 (67 to 72)                        Referent           
  Geographic region                                                                                               
    Europe/UK                  13 (54.2)                  57 (54 to 60)                  −1.7 (−10.7 to 7.3)    0.71
    Asia                        2 (8.3)                   56 (48 to 66)                  −8.8 (−26.4 to 8.8)    0.32
    Other                        0 (0)                         NA                                 NA             NA
    Multinational                0 (0)                         NA                                 NA             NA
    North America              9 (37.5)                   54 (48 to 62)                        Referent           
  VKA experience                                                                                                  
    NR/Mixed                   5 (20.8)                   51 (41 to 63)                  −5.7 (−34.7 to 23.3)   0.83
    No                         3 (12.5)                   63 (55 to 73)                  7.9 (−15.2 to 31.0)    0.65
    Yes                        17 (70.8)                  56 (54 to 59)                        Referent           
  Duration of VKA treatment                                                                                       
    ≥1 year                    17 (70.8)                  57 (54 to 60)                   9.1 (−0.5 to 18.7)    0.09
    \<1 year                   7 (29.2)                   53 (44 to 65)                        Referent           

AC = anticoagulation; CI = confidence interval; NA = not applicable; No. = number of study arms; NR = not reported; RCT = randomized controlled trial; UK = United Kingdom; VKA = Vitamin K Antagonists.

In the second meta-analysis, 30 of 43 studies (70%) reported an INR measure with thromboembolic events, 21 (49%) reported an INR with ischemic stroke, 32 (74%) reported INRs with major hemorrhage, and 16 (37%) reported an INR with ICH. INR data was incomplete in 58% of the studies that reported adverse events; not all events were reported with an INR measure. Thirty percent of the studies used previously reported INRs, allowing INR measures from 3 days up to 12 days prior to be considered as temporally related to the adverse event.

Overall, 57% of the thromboembolic events occurred at an INR \<2.0 (95% CI, 50-64%) and 42% of hemorrhagic events occurred at an INR \>3.0 (95% CI, 35 -- 51%) (Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). A high degree of heterogeneity was present for studies that reported thromboembolic and hemorrhagic events (I^2^ = 80% and 77% respectively); however, the presence of publication bias was deemed low (Egger's p = 0.31 and p = 0.69, respectively) (Additional file [1](#S1){ref-type="supplementary-material"}). When ischemic stroke and ICH were evaluated separately from other events, we found that 56% of ischemic strokes (95% CI, 48 -- 64%) and 45% of ICHs (95% CI, 29-63%) occurred at INRs \<2.0 and \>3.0, respectively, but a high degree of heterogeneity was still present (I^2^ = 76% and 85%, respectively) (Figures [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}). Furthermore, when studies that allowed previously reported INRs (more than 48 hours prior to an event) were excluded, we found a higher proportion of events that occurred outside the therapeutic range for 59% of thromboembolic events (95% CI, 51 -- 66%) and 47% of hemorrhagic events (95% CI, 37 -- 58%).

![**Results of random-effects meta-analysis of the proportion of thromboembolic events that occurred when INRs were below 2.0.** The squares represent individual studies, and the size of the square represents the weight given to each study in the meta-analysis. Error bars represent 95% confidence intervals. The diamond represents the combined results. List of studies shows name of first author and year of publication. CI = Confidence Interval.](1477-9560-12-14-2){#F2}

![**Results of random-effects meta-analysis of the proportion of major hemorrhagic events that occurred when INRs were above 3.0.** The squares represent individual studies, and the size of the square represents the weight given to each study in the meta-analysis. Error bars represent 95% confidence intervals. The diamond represents the combined results. List of studies shows name of first author and year of publication. CI = Confidence Interval.](1477-9560-12-14-3){#F3}

![**Results of random-effects meta-analysis of the proportion of ischemic strokes that occurred when INRs were below 2.0.** The squares represent individual studies, and the size of the square represents the weight given to each study in the meta-analysis. Error bars represent 95% confidence intervals. The diamond represents the combined results. List of studies shows name of first author and year of publication. CI = Confidence Interval.](1477-9560-12-14-4){#F4}

![**Results of Random-Effects Meta-Analysis of the Proportion of Intracranial Hemorrhages That Occurred When INRs Were Above 3.0.** The squares represent individual studies, and the size of the square represents the weight given to each study in the meta-analysis. Error bars represent 95% confidence intervals. The diamond represents the combined results. List of studies shows name of first author and year of publication. CI = Confidence Interval; ICH = Intracranial hemorrhage.](1477-9560-12-14-5){#F5}

Discussion
==========

In a pooled analysis of AF studies performed worldwide between 1990 and June 2013, we found patients spent only 61% of their TTR and only 56% of their measured INRs were in range. Moreover, when patients were out of range, they were more likely to be below range and at an increased risk of thrombosis, as compared to being above range with an increased risk of bleeding. While, thromboembolic and hemorrhagic events did occur in patients with a therapeutic INR; we demonstrated more than half of all thromboembolic events occurred when the INR was less than 2.0 and more than 40% of all hemorrhagic events happened at an INR \> 3.0. As such, the efficacy and safety of VKAs appear strongly tethered to the quality of INR control achieved.

Our meta-regression analyses showed three important findings. First, patients having their VKAs managed in the community setting spent significantly less TTR when compared to patients managed in an anticoagulation clinic or in a RCT setting. This data supports the growing body of literature demonstrating that patients whose care is managed in an anticoagulation clinic have better outcomes (improved TTR, lower rates of major bleeding and thrombosis, and decreased health care costs) than those managed in community practice \[[@B104]-[@B106]\]. The improved INR control in RCTs and anticoagulation clinics may be the result of increasing the frequency of monitoring, providing more organized care and focusing more on improving poor VKA-drug persistence (as low as 68% at 6-months) \[[@B107],[@B108]\] than typically done in community settings. Unfortunately, not all patients receiving a VKA have access to anticoagulation clinics \[[@B109]\]. In fact, it is estimated that only about one-third of patients receiving a VKA in the US have access to an anticoagulation clinic due to time, distance, economic or other access-to-care issues. Second, patients who were VKA-naive spent significantly less time in the therapeutic range than VKA-experienced patients. This is likely a result of poorer INR control early on in treatment, as clinicians attempt to control the INR within the narrow therapeutic window without any prior knowledge of the patient's-specific dosing requirements. It may also suggest that patients learn to manage their VKA better over time. This observation may warrant researchers to stratify analyses according to whether patients are newly initiated to warfarin or experienced warfarin patients. Finally, people in North America spent significantly less time in the therapeutic range than those in Europe or the UK. This may be a result of North America's near exclusive use of warfarin, which has been shown in previous analyses to result in as much as a 9% lower TTR compared to other VKAs \[[@B6]\], as well as, North America's less wide-spread use of proven strategies to increase TTR such as and anticoagulation clinics as noted above \[[@B6],[@B8],[@B9],[@B109]\] and patient self-monitoring \[[@B6]\].

Our systematic review and meta-analysis supports and extends the knowledge of VKA use in contemporary practice. Our TTR or PINRR results are in general agreement with the systematic reviews by van Walraven et al. \[[@B6]\] and Cios et al. \[[@B9]\], but these analyses included all therapeutic indications for VKAs, which lowers their applicability for an AF-specific population. The meta-analyses by Baker et al. \[[@B8]\] and Wan et al. \[[@B7]\] focused on AF only populations, but each had some limitations. The Baker meta-analysis was limited to a United States population, and therefore, contained only 8 studies. Despite this, they did find that care within an anticoagulation clinic yielded a higher TTR than usual care in the community, a finding we extend into the worldwide AF population as well. The Wan meta-analysis was published in 2008, evaluated a worldwide AF population and found similar TTR and PINRR results to our own. However, they only included 47 VKA groups from 38 published studies. They found that TTR was significantly correlated with PINRR in retrospective studies and TTR was significantly negatively correlated to both major hemorrhage and thromboembolic events. Given the intense focus on thromboembolism in contemporary practice, our literature search was able to almost double the number of articles included in the Wan et al. by updating the search to 2013. Over the 5 years since the publication of Wan et al.'s meta-analysis, we found the TTR and PINRR to be only slightly increased (overall TTR increased from 57% to 61% and PINRR from 51 to 56%) \[[@B7]\]. This suggests that we still have a long way to go to enhance the quality of INR control. Our findings that the majority of thromboembolic events happen in AF patients when the INR is less than 2.0 and more than 40% of hemorrhages occur when an INR is greater than 3.0 confirms the findings from the systematic review of Oake et al. \[[@B10]\]. Their systematic review did not limit the studies to an AF population and was published in 2009, so our findings through June 2013 in the target AF population extend knowledge in this area as well.

There are several limitations of our meta-analysis worth discussion. First, the potential for publication bias and possibility of missed eligible articles could exist. However, we consider this risk to be minimized due to our systematic search strategy and manual backwards citation tracking. In addition, having such a large cadre of studies, as we do in our meta-analysis, minimizes the impact that a missed individual study might have on our pooled result. Another limitation of our analysis includes the fact that very few identified studies evaluated PINRR. As a result, our meta-regression analysis was likely underpowered; although similar trends could be seen to TTR. Future evaluation of PINRR should be conducted when there is a sufficient literature base to make firmer conclusions. Another limitation of our analysis is the possibility of a language bias; as we only included English language studies which may not represent all of the published evidence. Finally, there was a high degree of statistical heterogeneity observed in our analyses, suggesting that the included studies varied clinically and/or methodologically. However, this was one of our rationales for conducting meta-regression. In our meta-regression analyses, we found some potential explanations for the identified heterogeneity; although there may still be additional factors that we could not think to evaluate or for which there is insufficient data to allow evaluation.

Conclusions
===========

Patients on VKAs for thromboembolism prevention in AF are frequently outside the normal INR range and tend to be under-anticoagulated rather than over-anticoagulated. While, thromboembolic and hemorrhagic events do occur patients with a therapeutic INR; patients with an INR \< 2.0 make up many of the cases of thromboembolism, while those with an INR \> 3.0 make up many of the cases of major hemorrhage. Managing anticoagulation outside of a clinical trial or anticoagulation clinic is associated with poorer INR control as is initiation of therapy in patients who are VKA-naïve. Patients in Europe/UK have better INR control than those in North America.
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